United States Nuclear Regulatory Commission - Protecting People and the Environment

Edward Margerrison

Ed is the Director for the Office of Science and Engineering Laboratories at the Center for Devices and Radiological Health, US FDA. The Office is responsible for providing technical expertise and analyses in support of the regulatory processes within CDRH. In addition, the c300 scientists and engineers engage in representing the Agency on International standards organizations, provide scientific guidance for policy, and "futureproof" the Center for technologies making their way into novel medical devices.

Previously, he was President and CEO of Ortho Regenerative Technologies, a biotech startup based in Montreal, developing novel biomaterial approaches to surgical soft tissue repair. During this appointment, Ed steered the company to listing on the Canadian stock exchange, and started the regulatory process for the technology with the Center for Biologics at FDA.

He has also held senior positions at Zimmer Biomet (Vice President of Biologics), where he was primarily responsible for the cartilage repair business, resulting in the division becoming Zimmer’s Business Unit of the Year for 2014, and other positions in both the pharmaceutical (Akela Pharma) and Orthopedics (Smith & Nephew) industries.

Page Last Reviewed/Updated Wednesday, July 17, 2019